Psioxus to Elicit Immunological Response of Oncolytic Vaccine
By Nuala Moran
Tuesday, June 25, 2013
LONDON – While oncolytic cancer vaccines are advancing in the clinic, there is as yet limited understanding of how they exert their effects on the immune system after infected tumor cells burst. That process releases more virus to infect and lyse more tumor cells, but it also discharges inflammatory mediators and cell-specific tumor antigens that prompt the immune system to react against the tumor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.